Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > New Chemical Entities, Drug Leads


[Search within category]

Potassium Channel Inhibitor for Autoimmune Disease Therapy

This invention is an analog of a naturally occurring potassium channel inhibitor. This potassium channel inhibitor has the potential to provide a great benefit to patients that suffer from autoimmune diseases.

Treatment Of Lysosomal Storage Disorders

UCLA researchers in the Departments of Neurology have developed a novel treatment for Lysosomal-storage diseases (LSDs) with neurological impairment.

Novel Methods for Studying Ceramide In Vivo and Inducing Ceramide-Induced Apoptosis

Mammalian cells synthesize thousands of distinct lipids, yet the function of many of these lipid species is unknown. Ceramides are a chemically diverse class of sphingolipids that have critical roles in a wide range of biological pathways, but poor cell permeability and lack of selectivity in endogenous synthesis pathways have hampered direct study of their effects. Despite their high biological interest, ceramides have been difficult to study because of their impermeability to the cell membrane.

New Drug Class for Treating Multiple Sclerosis

UCLA researchers from the Department of Molecular & Medical Pharmacology have developed a novel drug class for the treatment of multiple sclerosis.

Novel Clotrimazole Analogs As Blockers Of Intermediate Conductance Kca Channels

Researchers at the University of California, Davis, have developed a method for preparing therapeutically effective amounts of triarylmethane compounds for immunosuppressive treatment of autoimmune disorders, graft rejection, and graft or host disease.

Identification And Development Of Dual nSMase2-AChE Inhibitors For Neurodegenerative Disorders

UCLA researchers in the Department of Neurology, and the Department of Chemistry & Biochemistry have developed small molecule inhibitors of both the neutral sphingomyelinase 2 (nSMase2) and acetylcholinesterase (AChE) as novel therapeutics for neurodegenerative disorders caused by protein aggregation.

New Molecular Tweezers Against Neurological Disorders And Viral Infections

UCLA researchers in the Department of Neurology with an international team of scientists have developed several new molecular tweezer derivatives with novel synthesis methods that significantly improved the therapeutic efficacy and pharmacokinetic characteristics of the drug candidates.

Drug Combinations For Treatment Of Tinnitus, Vertigo, and Headache

UC Irvine researchers propose various combinations of medications for treatment of tinnitus and vertigo.

A High Potency CYP3A4 Inhibitor for Pharmacoenhancement of Drugs

      CYP3A4 is the most clinically relevant drug metabolizing enzyme in the body, as it is responsible for the oxidation and breakdown of ~60% of current drugs on the market.  Researchers at UCI have developed novel CYP3A4 inhibitors, that are highly potent and more specific, exhibit fewer side effects, and are both cheaper, and easier to-synthesize than current commercially available CYP3A4 inhibitors. 

Novel Synthesis of Streptogramin A Antibiotics

A modular, scalable, chemical synthesis platform that produces new Streptogramin A class antibiotic candidates.

A Novel Mixture for Intravenous Sedation

UCLA researchers from the Department of Anesthesiology and Perioperative Medicine have developed a novel anesthetic mixture which combines anxielytic, narcotic, and sedation effects in a safe, effective solution.

Novel Non-Peptidomimetic Prenyltransferase Inhibitors

UCLA Researchers in the Department of Chemistry & Biochemistry and School of Medicine have synthesized a series of small molecule therapeutics against GGTase-I and GGTase-II, both of which are critical oncology drug targets.

Antibody-Interferon Fusion Proteins For Enhancing Adoptive T Cell Therapies For The Treatment Of Cancer

UCLA researchers in the Departments of Medicine and Microbiology, Immunology and Molecular Genetics have developed a novel combination therapy for enhanced efficacy of adoptive T cell therapies.

BMP Binding Proteins and Prosthetic Surfaces

UCLA researchers have developed a method to attach and enhance the activity of bone growth factors to prostheses through BMP binding proteins to increase the integration of prostheses and bone.

BBP as a Complexed Carrier for Bone Growth Factors

UCLA researchers have identified a BMP binding peptide that binds to bone growth factors to increase their residence time at the site of implantation for treatment of bone defects.

Use of Il-10 Inhibitors as Adjuvants for Vaccination or Immunotherapy

Researchers at the University of California, Davis have developed a process of administering inhibitors of Interleukin 10 (IL-10) signaling concomitantly with a vaccine or other immunostimulus, so that responses to vaccination occur in the absence of such signaling.

Nanoparticulate Mineralized Collagen Glycosaminoglycan Scaffold With An Anti-Resorption Factor

Researchers in the Division of Plastic and Reconstructive Surgery at the UCLA David Geffen School of Medicine and the Institute of Genomic Biology at the University of Illinois Urbana Champaign (UIUC) have developed novel methods to incorporate anti-resorption factor into nanoparticulate mineralized collagen glycosaminoglycan scaffold to maximize bone regeneration.

Allosteric BACE Inhibitors For Treatment Of Alzheimer’s Disease

UCLA researchers from the Department of Neurology have discovered a new class of drug candidates for Alzheimer’s disease. These small molecule compounds can specifically inhibit target enzymes to prevent target protein cleavage through an allosteric mechanism, preventing off-target side effect.

Humanized Antibodies to the Extracellular Domains of Human N-Cadherin

UCLA researchers in the Department of Molecular and Medical Pharmacology have developed humanized antibody therapies for invasive prostate and bladder cancers that express N-cadherin.

Antibody Selection to Prevent or Treat Alzheimer’s Disease

Therapeutic antibodies have been developed to prevent or slow the cognitive decline in Alzheimer’s disease (AD) but with limited clinical success to date. These treatment failures suggest that antibodies vary in their therapeutic efficacy and that more effective antibodies or combinations of antibodies need to be identified. To address this issue, researchers at UCI have developed a novel screening platform that can identify antibodies that may prevent or treat AD or other neurodegenerative disorders with high efficacy from human blood.

Bioavailable Dual sEH/PDE4 Inhibitor for Inflammatory Pain

Researchers at the University of California, Davis, have developed a dual soluble epoxide hydrolase (sEH)/ phosphodiesterase 4 (PDE4) inhibitor for the treatment of inflammatory pain.

Small Molecule sEH Inhibitors to Treat Alpha-Synuclein Neurodegenerative Disorders

Researchers at the University of California, Davis have developed small molecule inhibitors to prevent or reverse the progression of neurodegenerative diseases or symptoms.

PTUPB Compound Potentiates Cisplatin-Based-First Line Therapies with No Additional Toxicity

Researchers at the University of California, Davis have discovered a compound that inhibits both cyclooxygenase-2 (COX-2) /soluble epoxide hydrolase (sEH) to improve effectiveness of chemotherapy while protecting normal tissue from cisplatin toxicity.

Joint Pharmacophoric Space through Geometric Features

Pharmacophore analysis through examination of Joint Pharmacophore Space of chemical compounds, targets, and chemical/biological properties.

Selective Voltage Gated KV1.3 Potassium Channel Inhibitors

Researchers at the University of California, Davis, have discovered a composition of 5-phenoxyalkoxypsoralens that inhibits potassium channels to treat autoimmune diseases and disorders that involve abnormal homeostasis, body weight and peripheral insulin sensitivity.

  • Go to Page: